enGene Inc. Common Stock (ENGN)
| Bid | 3.66 |
| Market Cap | 189.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -69.05M |
| EPS (ttm) | -1.48 |
| PE Ratio (ttm) | -2.51 |
| Forward PE | -1.72 |
| Analyst | Buy |
| Ask | 3.77 |
| Volume | 45,110 |
| Avg. Volume (20D) | 50,970 |
| Open | 3.71 |
| Previous Close | 3.74 |
| Day's Range | 3.63 - 3.74 |
| 52-Week Range | 3.50 - 16.00 |
| Beta | -0.37 |
About ENGN
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calm...
Analyst Forecast
According to 7 analyst ratings, the average rating for ENGN stock is "Buy." The 12-month stock price forecast is $25.5, which is an increase of 587.24% from the latest price.
Stock Forecasts
3 weeks ago · businesswire.com
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity...
1 month ago · businesswire.com
enGene to Present at the Stifel 2025 Virtual Targeted Oncology ForumBOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Exec...
